Literature DB >> 11201884

Chemoprophylaxis of leprosy in the southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years.

L N Nguyen1, J L Cartel, J H Grosset.   

Abstract

In 1988, a programme of leprosy chemoprophylaxis, employing a supervised, single 25 mg/kg dose of rifampicin, was implemented in the Southern Marquesas Islands. Of the 2786 inhabitants, 2751 (98.7%) were treated. In addition, 3144 South Marquesans living elsewhere in French Polynesia were administered the same chemoprophylaxis. During the following 10 years, seven leprosy patients were detected among those who had been administered chemoprophylaxis. Of these, two were very likely missed cases of leprosy, and cannot be considered a failure of chemoprophylaxis. The epidemiometric projection model, based on cases of leprosy observed in the Southern Marquesas during the 20 years preceding implementation of the programme, predicted that 17 leprosy cases could be expected in the South Marquesan population if no chemoprophylaxis were given. In fact, only five cases were detected in the treated population, a number significantly smaller than 17, suggesting that the chemoprophylaxis was 70% effective, assuming that no change of detection rate would have occurred without chemoprophylaxis. However, during the 10 years following implementation of the chemoprophylaxis programme, the detection rate in the Polynesian population that was not administered chemoprophylaxis declined by about 50%. Therefore, the effectiveness of the chemoprophylaxis was only 35-40%.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11201884     DOI: 10.5935/0305-7518.20000064

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  10 in total

Review 1.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

Review 2.  The State of Affairs in Post-Exposure Leprosy Prevention: A Descriptive Meta-Analysis on Immuno- and Chemo-Prophylaxis.

Authors:  Anne Schoenmakers; Liesbeth Mieras; Teky Budiawan; Wim H van Brakel
Journal:  Res Rep Trop Med       Date:  2020-10-15

3.  Leprosy therapy, past and present: can we hope to eliminate it?

Authors:  P V S Prasad; P K Kaviarasan
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494

Review 4.  Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.

Authors:  Malcolm S Duthie; Marivic F Balagon
Journal:  Risk Manag Healthc Policy       Date:  2016-04-27

5.  Leprosy Post-Exposure Prophylaxis (LPEP) programme: study protocol for evaluating the feasibility and impact on case detection rates of contact tracing and single dose rifampicin.

Authors:  Tanja Barth-Jaeggi; Peter Steinmann; Liesbeth Mieras; Wim van Brakel; Jan Hendrik Richardus; Anuj Tiwari; Martin Bratschi; Arielle Cavaliero; Bart Vander Plaetse; Fareed Mirza; Ann Aerts
Journal:  BMJ Open       Date:  2016-11-17       Impact factor: 2.692

6.  Protocol, rationale and design of PEOPLE (Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar): a cluster randomized trial on effectiveness of different modalities of implementation of post-exposure prophylaxis of leprosy contacts.

Authors:  Nimer Ortuno-Gutierrez; Assoumani Younoussa; Andriamira Randrianantoandro; Sofie Braet; Bertrand Cauchoix; Stéphanie Ramboarina; Abdallah Baco; Aboubacar Mzembaba; Zahara Salim; Mohamed Amidy; Saverio Grillone; Jan Hendrik Richardus; Bouke C de Jong; Epco Hasker
Journal:  BMC Infect Dis       Date:  2019-12-05       Impact factor: 3.090

Review 7.  Leprosy: A Review of Epidemiology, Clinical Diagnosis, and Management.

Authors:  Kou-Huang Chen; Cheng-Yao Lin; Shih-Bin Su; Kow-Tong Chen
Journal:  J Trop Med       Date:  2022-07-04

Review 8.  Chemoprophylaxis of Tropical Infectious Diseases.

Authors:  William J H McBride
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-18

9.  Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.

Authors:  Shannon M Lenz; Jaymes H Collins; Nashone A Ray; Deanna A Hagge; Ramanuj Lahiri; Linda B Adams
Journal:  PLoS Negl Trop Dis       Date:  2020-09-16

10.  Population-wide administration of single dose rifampicin for leprosy prevention in isolated communities: a three year follow-up feasibility study in Indonesia.

Authors:  Anuj Tiwari; Steaven Dandel; Rita Djupuri; Liesbeth Mieras; Jan Hendrik Richardus
Journal:  BMC Infect Dis       Date:  2018-07-11       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.